JP2018526981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526981A5 JP2018526981A5 JP2018501159A JP2018501159A JP2018526981A5 JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5 JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cdr2
- cdr1
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021168124A JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| EPPCT/EP2016/050296 | 2016-01-08 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
| PCT/EP2016/066845 WO2017009442A1 (en) | 2015-07-15 | 2016-07-14 | Humanized or chimeric cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Division JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526981A JP2018526981A (ja) | 2018-09-20 |
| JP2018526981A5 true JP2018526981A5 (OSRAM) | 2019-08-29 |
Family
ID=57757079
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501159A Pending JP2018526981A (ja) | 2015-07-15 | 2016-07-14 | ヒト化またはキメラｃｄ３抗体 |
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11359015B2 (OSRAM) |
| EP (1) | EP3322727A1 (OSRAM) |
| JP (3) | JP2018526981A (OSRAM) |
| KR (2) | KR20250048113A (OSRAM) |
| CN (3) | CN120842408A (OSRAM) |
| AU (2) | AU2016293073B2 (OSRAM) |
| BR (1) | BR112018000696A2 (OSRAM) |
| CA (1) | CA2992380A1 (OSRAM) |
| EA (1) | EA201890305A1 (OSRAM) |
| IL (2) | IL256562B2 (OSRAM) |
| MX (2) | MX395317B (OSRAM) |
| NZ (1) | NZ739028A (OSRAM) |
| UA (1) | UA128057C2 (OSRAM) |
| WO (1) | WO2017009442A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| NZ715896A (en) | 2013-07-05 | 2022-02-25 | Genmab As | Humanized or chimeric cd3 antibodies |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| IL322509A (en) * | 2017-03-09 | 2025-10-01 | Genmab As | Antibodies against PD-L1 |
| WO2018208877A1 (en) * | 2017-05-09 | 2018-11-15 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| KR102324568B1 (ko) | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120 및 CD3을 표적화하는 다중특이적 항체 |
| SG11202008399QA (en) | 2018-03-12 | 2020-09-29 | Genmab As | Antibodies |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| KR20210063351A (ko) * | 2018-08-28 | 2021-06-01 | 암브룩스, 인코포레이티드 | 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도 |
| US20230002487A1 (en) * | 2019-06-07 | 2023-01-05 | Adimab, Llc | High affinity anti-cd3 antibodies, and methods for their generation and use |
| US20220280618A1 (en) * | 2019-07-29 | 2022-09-08 | The Administrators Of The Tulane Educational Fund | Antibodies to candida and uses thereof |
| EP4028424A1 (en) | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| KR20220154757A (ko) | 2020-03-18 | 2022-11-22 | 젠맵 에이/에스 | B7h4에 결합하는 항체 |
| IL297986A (en) * | 2020-05-08 | 2023-01-01 | Genmab As | Bispecific antibodies against cd3 and cd20 |
| JP2023541858A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| BR112023004321A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma de célula b grande difusa em um sujeito humano |
| US20230365714A1 (en) | 2020-10-02 | 2023-11-16 | Genmab A/S | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 |
| KR20240004949A (ko) | 2021-05-07 | 2024-01-11 | 젠맵 에이/에스 | B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물 |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| MX2024003615A (es) * | 2021-10-08 | 2024-04-09 | Genmab As | Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3). |
| CN115368446B (zh) * | 2022-07-19 | 2025-08-08 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024208898A1 (en) | 2023-04-05 | 2024-10-10 | Genmab A/S | Pharmaceutical compositions comprising antibodies binding to cd30 and cd3 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| CN105884893A (zh) | 2002-07-18 | 2016-08-24 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| RU2561457C2 (ru) | 2007-04-03 | 2015-08-27 | Эмджен Рисерч (Мьюник) Гмбх | Cd3-эпсилон-связывающий домен с межвидовой специфичностью |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| EP3482769B1 (en) | 2008-12-19 | 2024-05-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US20140170149A1 (en) * | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| BR112013029893A2 (pt) | 2011-05-21 | 2017-05-30 | Macrogenics Inc | molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
| CN104822704B (zh) * | 2012-06-14 | 2020-02-14 | 医疗生物科学有限公司 | 针对分化簇3(cd3)的人源化的抗体 |
| EP2895203A4 (en) * | 2012-06-15 | 2016-09-28 | Imaginab Inc | ANTIGENBINDING CONSTRUCTS FOR CD3 |
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
| ES2744267T3 (es) | 2012-11-21 | 2020-02-24 | Pharmabcine Inc | Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo |
| NZ715896A (en) | 2013-07-05 | 2022-02-25 | Genmab As | Humanized or chimeric cd3 antibodies |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
-
2016
- 2016-07-14 EA EA201890305A patent/EA201890305A1/ru unknown
- 2016-07-14 IL IL256562A patent/IL256562B2/en unknown
- 2016-07-14 IL IL310467A patent/IL310467A/en unknown
- 2016-07-14 KR KR1020257009196A patent/KR20250048113A/ko active Pending
- 2016-07-14 CA CA2992380A patent/CA2992380A1/en active Pending
- 2016-07-14 CN CN202511003204.5A patent/CN120842408A/zh active Pending
- 2016-07-14 MX MX2018000347A patent/MX395317B/es unknown
- 2016-07-14 EP EP16739459.2A patent/EP3322727A1/en active Pending
- 2016-07-14 WO PCT/EP2016/066845 patent/WO2017009442A1/en not_active Ceased
- 2016-07-14 JP JP2018501159A patent/JP2018526981A/ja active Pending
- 2016-07-14 UA UAA201801453A patent/UA128057C2/uk unknown
- 2016-07-14 CN CN201680054638.0A patent/CN108368172B/zh active Active
- 2016-07-14 BR BR112018000696A patent/BR112018000696A2/pt active Search and Examination
- 2016-07-14 KR KR1020187004157A patent/KR102786353B1/ko active Active
- 2016-07-14 CN CN202210585379.1A patent/CN114989302B/zh active Active
- 2016-07-14 NZ NZ739028A patent/NZ739028A/en unknown
- 2016-07-14 US US15/744,317 patent/US11359015B2/en active Active
- 2016-07-14 AU AU2016293073A patent/AU2016293073B2/en active Active
-
2018
- 2018-01-09 MX MX2022011002A patent/MX2022011002A/es unknown
-
2021
- 2021-10-13 JP JP2021168124A patent/JP7604351B2/ja active Active
-
2022
- 2022-05-09 US US17/739,934 patent/US20230027394A1/en active Pending
- 2022-05-09 US US17/739,940 patent/US20220389101A1/en active Pending
- 2022-05-09 US US17/739,923 patent/US20220380464A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201733A patent/AU2023201733A1/en active Pending
-
2024
- 2024-12-11 JP JP2024216521A patent/JP2025038049A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526981A5 (OSRAM) | ||
| JP2020048564A5 (OSRAM) | ||
| JP2016529882A5 (OSRAM) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| CN107614529B (zh) | Pd-l1抗体、其抗原结合片段及其医药用途 | |
| US9409979B2 (en) | Acceptor framework for CDR grafting | |
| JP2017505121A5 (OSRAM) | ||
| JP2019501883A5 (OSRAM) | ||
| EP2050764A1 (en) | Novel polyvalent bispecific antibody format and uses thereof | |
| JP2020508655A5 (OSRAM) | ||
| JPWO2019129221A5 (OSRAM) | ||
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2018522888A5 (OSRAM) | ||
| JP2020502233A5 (OSRAM) | ||
| TW202200620A (zh) | 抗flt3抗體及組合物 | |
| WO2021013142A1 (zh) | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 | |
| US20240034815A1 (en) | Heterodimeric antibodies that bind cd3 and gpc3 | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JPWO2022111425A5 (OSRAM) | ||
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies | |
| CN113330037A (zh) | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 | |
| Kipriyanov | Generation of antibody molecules through antibody engineering | |
| JP2016506974A (ja) | Ｃｄｒグラフトのためのアクセプターフレームワーク | |
| JPWO2022218380A5 (OSRAM) | ||
| WO2019072274A1 (zh) | 一种激动型4-1bb单克隆抗体 |